Outlook 2021: Medtechs Must Look To Late 2021 And 2022 For A Return To Normal Times
Medtech is as attractive as it has ever been says Jefferies Healthcare
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
You may also be interested in...
The COVID-19 pandemic has fundamentally changed health care and the life sciences, KPMG analyst Kristin Pothier concludes in a new report on the medtech investment outlook.
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.
The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.